Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 1:18:1533033819870767.
doi: 10.1177/1533033819870767.

A Collimator Setting Optimization Algorithm for Dual-Arc Volumetric Modulated Arc Therapy in Pancreas Stereotactic Body Radiation Therapy

Affiliations

A Collimator Setting Optimization Algorithm for Dual-Arc Volumetric Modulated Arc Therapy in Pancreas Stereotactic Body Radiation Therapy

Xinyi Li et al. Technol Cancer Res Treat. .

Abstract

Purpose: To optimize collimator setting to improve dosimetric quality of pancreas volumetric modulated arc therapy plan for stereotactic body radiation therapy.

Materials and methods: Fifty-five volumetric modulated arc therapy cases in stereotactic body radiation therapy of pancreas were retrospectively included in this study with internal review board approval. Different from the routine practice of initializing collimator settings with a template, the proposed algorithm simultaneously optimizes the collimator angles and jaw positions that are customized to the patient geometry. Specifically, this algorithm includes 2 key steps: (1) an iterative optimization algorithm via simulated annealing that generates a set of potential collimator settings from 39 cases with pancreas stereotactic body radiation therapy, and (2) a multi-leaf collimator modulation scoring system that makes the final decision of the optimal collimator settings (collimator angles and jaw positions) based on organs at risk sparing criteria. For validation, the other 16 cases with pancreas stereotactic body radiation therapy were analyzed. Two plans were generated for each validation case, with one plan optimized using the proposed algorithm (Planopt) and the other plan with the template setting (Planconv). Each plan was optimized with 2 full arcs and the same set of constraints for the same case. Dosimetric results were analyzed and compared, including target dose coverage, conformity, organs at risk maximum dose, and modulation complexity score. All results were tested by Wilcoxon signed rank tests, and the statistical significance level was set to .05.

Results: Both plan groups had comparable target dose coverage and mean doses of all organs at risk. However, organs at risk (stomach, duodenum, large/small bowel) maximum dose sparing (D0.1 cc and D0.03 cc) was improved in Planopt compared to Planconv. Planopt also showed lower modulation complexity score, which suggests better capability of handling complex shape and sparing organs at risk .

Conclusions: The proposed collimator settings optimization algorithm successfully improved dosimetric performance for dual-arc pancreas volumetric modulated arc therapy plans in stereotactic body radiation therapy of pancreas. This algorithm has the capability of immediate clinical application.

Keywords: IMRT; SBRT; VMAT; collimator settings; optimization; pancreas cancer; simulated annealing; treatment planning.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flowchart of the proposed collimator angle optimization algorithm. Red blocks are inputs, and green block is output. Xd indicates the larger jaw opening value of the dual-arc pair in the X direction (multi-leaf collimator [MLC] motion direction).
Figure 2.
Figure 2.
Dose distribution comparison of Planopt (left) and Planconv (right) from a selected case. Yellow arrows in (A) and (B) indicate the comparison of dose conformity, and blue arrows in (C) and (D) indicate the comparison of organs at risk (OAR) sparing. Primary planned target volume (PTV25 Gy) is shown in cyan, and PTV33 Gy is shown in red. Proximal OARs are shown in yellow (stomach), dark blue (duodenum), and dark green (large bowel). Isodose lines are shown in yellow (3300 cGy) and white (3135 cGy). Planopt indicates proposed algorithm; Planconv, plan with the template setting.
Figure 3.
Figure 3.
Comparison of the dose statistics (normalized to prescription dose value) in Planconv and Planopt.*Statistical significance. Planopt indicates proposed algorithm; Planconv, plan with the template setting
Figure 4.
Figure 4.
Comparisons of the modulation complexity score, weighed multi-leaf collimator (MLC) opening, and total MU between Planconv and Planopt. Both tests were of statistical significance. Planopt indicates proposed algorithm; Planconv, plan with the template setting.
Figure 5.
Figure 5.
Illustration of the initial collimator settings in the dual collimator angles plane. Each pixel value in the figure is the occurrence count of the desirable collimator angle pairs of 39 library cases. Please note that each case could have multiple desirable collimator angle pairs with similar Xd. Red dots represent the selected initial CSa,i.
Figure 6.
Figure 6.
Collimator angle pair results from (A) simulated annealing optimization and (B) exhausting search (red dots) overlapped to the results from simulated annealing optimization. These 2 methods show good coincidence with each other.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J Clini. 2018;68(1):7–30. - PubMed
    1. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Medi. 2012;6(5):597–612. - PMC - PubMed
    1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–620. - PMC - PubMed
    1. Tempero MA, Malafa MP, Al-Hawary M. et al. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2010;8(9):1028–1061. - PubMed
    1. Simianu VV, Zyromski NJ, Nakeeb A, Lillemoe KD. Pancreatic cancer: progress made. Acta Oncol. 2010:49(4):407–417. - PubMed

MeSH terms